key: cord-0917070-j2r68vpq
authors: Miller, Ryan; Ashraf, Ambika P.; Gourgari, Evgenia; Gupta, Anshu; Kamboj, Manmohan K.; Kohn, Brenda; Lahoti, Amit; Mak, Daniel; Mehta, Shilpa; Mitchell, Deborah; Patel, Neha; Raman, Vandana; Reynolds, Danielle G.; Yu, Christine; Krishnan, Sowmya
title: SARS‐CoV‐2 infection and paediatric endocrine disorders: Risks and management considerations
date: 2021-06-03
journal: Endocrinol Diabetes Metab
DOI: 10.1002/edm2.262
sha: c43d4752ba3e49248ddba5a7491ea6d29a46f1f5
doc_id: 917070
cord_uid: j2r68vpq

BACKGROUND: Coronavirus‐19 (COVID‐19) is a disease caused by the SARS‐CoV‐2 virus, the seventh coronavirus identified as causing disease in humans. The SARS‐CoV‐2 virus has multiple potential pathophysiologic interconnections with endocrine systems, potentially causing disturbances in glucose metabolism, hypothalamic and pituitary function, adrenal function and mineral metabolism. A growing body of data is revealing both the effects of underlying endocrine disorders on COVID‐19 disease outcome and the effects of the SARS‐CoV‐2 virus on endocrine systems. However, comprehensive assessment of the relationship to endocrine disorders in children has been lacking. CONTENT: In this review, we present the effects of SARS‐CoV‐2 infection on endocrine systems and review the current literature on complications of COVID‐19 disease in underlying paediatric endocrine disorders. We provide recommendations on management of endocrinopathies related to SARS‐CoV‐2 infection in this population. SUMMARY AND OUTLOOK: With the surge in COVID‐19 cases worldwide, it is important for paediatric endocrinologists to be aware of the interaction of SARS‐CoV‐2 with the endocrine system and management considerations for patients with underlying disorders who develop COVID‐19 disease. While children and adults share some risk factors that influence risk of complications in SARS‐CoV‐2 infection, it is becoming clear that responses in the paediatric population are distinct and outcomes from adult studies cannot be extrapolated. Evidence emerging from paediatric studies provides some guidance but highlights the need for more research in this area.

Coronavirus disease is caused by the SARS-CoV-2 virus, the seventh coronavirus identified as causing disease in humans. Angiotensin-converting enzyme 2 (ACE2) is considered to be the primary receptor mediating SARS-CoV-2 infection. 1 Binding of SARS-CoV-2 to ACE2 triggers a cascade leading to activation of the NF-kB pathway, increasing proinflammatory cytokines and chemokines to very high levels, leading to the development of acute respiratory distress syndrome (ARDS) seen in severe COVID-19 disease. 2, 3 Lethality of ARDS and non-pulmonary complications in COVID-19 is thought to be due to cytokine storm in which immune and nonimmune cells release large amounts of proinflammatory cytokines that cause damage within and beyond the respiratory system. 4 Children and adolescents were initially thought to experience similar but less severe symptoms and complications of SARS-CoV-2 infection. 5 It is now apparent that children experience unique manifestations of SARS-CoV-2 infection, including multisystem inflammatory syndrome (MIS-C) and distinct endocrine responses. 6 In this paper, we present what is currently known regarding the Thus, it is essential for the paediatric endocrine community to understand the manifestations of this disease and the limits of our current knowledge in order to provide optimal care of children in the COVID-19 era.

The SARS-CoV-2 virus has multiple pathophysiologic interconnections with endocrine systems with the potential to cause disturbances in pituitary, adrenal and thyroid function, glucose metabolism and mineral metabolism. Existing data are generally favourable in terms of endocrine complications of COVID-19 in the paediatric population.

Similarities between COVID-19, SARS and MERS suggest that the virus may gain access to the central nervous system, including the hypothalamus, via the olfactory bulb. 8 Observational studies in adults have demonstrated disruption of posterior pituitary function and acute onset of syndrome of inappropriate antidiuretic hormone (SIADH) in COVID-19. 9-11 Hypothalamic/pituitary dysfunction has been described in SARS survivors. 12 However, the only evidence of pituitary involvement in COVID-19 is a finding of pituitary stalk involvement by MRI in two adult patients; to date, there are no reports of pituitary hormone deficiencies in either adults or children with There are data to suggest risk of both adrenal and thyroid involvement in adults with COVID-19. Acutely ill adults with COVID-19 disease were found to have higher cortisol levels than those without COVID-19 in one study, but with a reverse correlation between degree of cortisol response and survival rate in those who were COVID-19-positive. 14 Adrenal involvement has also been shown by CT (acute adrenal infarction) and post-mortem studies in adults with severe COVID-19 and SARS-CoV-2 infection. 15, 16 Both thyrotoxicosis (via association with higher IL-6 levels) and hypothyroidism have been identified in adults with COVID-19. [17] [18] [19] ACE2 is highly expressed in thyroid tissue, and to a lesser extent in adrenal tissue, while children may theoretically be at risk, thyroid and adrenal disease in children with COVID-19 and multisystem inflammatory syndrome in children (MIS-C) have not been reported. 20 SARS-CoV-2 infection may have a diabetogenic effect independent of the stress response associated with severe illness, as ACE2 is highly expressed in pancreatic islet cells. 21 New onset of diabetes mellitus has been described in adults with COVID-19 but not children. 22 abnormalities. 31 In patients with DI, the risk of hypernatraemia increases in acute illness due to factors including reduced fluid intake, increased insensible losses and inability to tolerate oral desmopressin; adipsic patients with DI are at marked risk of severe hypernatraemia, which may be complicated by venous thrombosis. [32] [33] [34] [35] As with other viral infections, COVID-19 is likely to increase risk of adrenal crisis and respiratory complications in patients with adrenal insufficiency (including those on corticosteroid replacement therapy); however, this has not specifically been addressed in either adults or children.

Currently, there are no data indicating increased risk of acquiring SARS-CoV-2 infection or altered disease course in children and adolescents with underlying thyroid disorders. However, it is important to keep in mind that patients with Graves' disease treated with antithyroid drug (ATD) therapy are at higher risk of agranulocytosis and secondary infections. 36 This is particularly important as data from one study showed that half of COVID-19 non-survivors experienced a secondary infection. 37 Underlying thyroid disease, including hypothyroidism, does appear to be a risk factor for a more severe disease course in adults with COVID-19. [38] [39] [40] It has been well documented that adults with diabetes mellitus, obesity and hypertension are at higher risk COVID-19 infection and experience higher rates of complications and death. [40] [41] [42] [43] [44] The T1D Exchange has published data on 64 adults with T1D; 33 were COVID-19-positive and 31 had COVID-19-like symptoms but were either not tested or were COVID-19-negative. 65.5% of individuals were <19 years of age. 45 The COVID-19-positive group was found to have a higher mean HbA1C (8.5% vs. 8%) were more likely to present in DKA (45.5% vs. 13.3%) and required a higher level of care compared with the COVID-like group. A population-based study in England showed that people with an HbA1C of 86 mmol/mol (10.0%) or higher compared with people with an HbA1C of 48-53 mmol/mol (6.5-7.0%) had increased COVID-19-related mortality (hazard ratio

[HR] 2·23 [95% CI 1·50-3·30, p < .0001] in T1D). 46 T1D Exchange data in the paediatric population demonstrated higher A1C, increased risk of hospitalization, non-Hispanic Black ethnicity and public insurance in children with T1D and COVID-19 (unpublished data). Children presenting with new-onset T1D may also be more likely to present in DKA and may have more severe DKA in during the coronavirus pandemic. 47 However, evidence to date suggests that children with T1D and COVID-19 do not have worse disease outcomes than those without diabetes. 48 Children with diabetes have faced unique challenges related to the COVID-19 pandemic, primarily related to widespread closures of schools and daycare centres. In a study from Greece, 34 children with T1D using insulin pumps and CGM did not have a significant increase in time in range during lockdown but did have greater blood glucose variability when compared to the pre-lockdown period. 49 The children in this study were also noted to have dramatic changes in meal schedules during lockdown. Restrictions related to the COVID-19

pandemic have resulted in decreased physical activity and dietary F I G U R E 1 Interactions between SARS-CoV-2 infection and endocrine systems changes as well as altered diabetes management behaviours, all of which may increase risk of poor nutrition, excessive weight gain and increased stress related to diabetes management. 48 Several studies have observed no difference in obesity rates between children with mild vs. severe COVID-19 disease. [50] [51] [52] While obesity in paediatric patients hospitalized for COVID-19 is not more frequent than in the general paediatric population, COVID-19 disease severity may be associated with obesity, as in adults. One report of 50 paediatric patients hospitalized with COVID-19 identified obesity as a risk factor for mechanical ventilation. 53 

Children with multiple pituitary hormone deficiencies may be at increased risk for COVID-19 complications and mortality, particularly if central AI is not managed adequately. In the absence of published data or guidelines, we recommend following established practices for managing pituitary hormone deficiencies in children.

Current guidance for adults with growth hormone deficiency recommends stopping growth hormone during hospitalization with COVID-19; however, there is a lack of data regarding the effects of growth hormone treatment during COVID-19 disease in children. 61 Management of adrenal insufficiency is addressed below.

Recommendations for management of central diabetes insipidus in patients with mild COVID-19 disease do not vary from usual recommendations for management of diabetes insipidus in the home setting. However, patients of all ages with diabetes insipidus are at risk of disturbed sodium balance during hospitalization and must be monitored closely. Hypernatraemia can be caused by failure to administer free water to patients who are unable to care for themselves, and inability to rely on thirst mechanism in critically ill patients. 62, 63 Patients are also vulnerable to hyponatraemia due to overtreatment of DI and excess ADH in the setting of COVID-19 pneumonia.

Treatment of DI with subcutaneous or oral desmopressin rather than intranasal desmopressin should be considered if there is concern for nasal congestion. In patients with severe COVID-19 illness, desmopressin should be administered intravenously. Urine osmolality and volume should be monitored, and serum sodium should be measured at frequent intervals (every 2-4 h) to help maintain eunatraemia.

Patients with COVID-19 may have severe respiratory disease including pulmonary oedema, as hypernatraemia has not been implicated as a risk factor for mortality in COVID-19, mild hypernatraemia may need to be tolerated under these circumstances to prevent pulmonary oedema. 31

Individuals who are steroid-dependent or suspected of having adrenal suppression should, first and foremost, take caution to avoid SARS-CoV-2 infection. Patients should be managed according to existing guidelines regarding stress dosing during symptomatic COVID-19 disease. 64, 65 The RECOVERY trial, a randomized, open-label trial of oral or intravenous dexamethasone (6 mg) daily vs. usual care, showed significant reduction in mortality in those receiving invasive mechanical ventilation and among those receiving oxygen without invasive mechanical ventilation, but not among those who were receiving no respiratory support at the time of randomization. 66 In guidance 

Viral illnesses can be more difficult to manage in individuals with diabetes due to increased insulin resistance and ketone production. 68, 69 As higher A1C is positively correlated with frequency of DKA in children with T1D, a significant proportion of the paediatric T1D population may be at increased risk of developing DKA in the setting of COVID-19 infection. 70, 71 It is imperative that clinicians take the time to review sick day guidelines and be available for guidance during times of illness to reduce the risk of developing DKA.

During COVID-19 illness, patients should be counselled to monitor blood glucose levels more frequently either via continuous glucose monitors or finger sticks. 72, 73 Insulin doses may need to be titrated more often and additional correction boluses of fast-acting insulin may be required to avoid severe hyperglycae- 

The shutting down of schools, camps and extracurricular sports and activities due to the pandemic has already had a profound impact on the health of children and adolescents due to social isolation, lack of activity and food insecurity in socioeconomically disadvantaged households. 75, 76 In one of our centres, we have observed a significant increase in children under 19 years of age presenting with newonset diabetes, with most of the increase in new cases accounted for by an increase in type 2 diabetes (RM; unpublished data). It is more important than ever to reinforce healthy eating habits and provide age-appropriate guidance on nutrition and physical activity. Racial/ ethnic and socioeconomic disparities have heightened health inequities particularly related to weight management during the COVID-19 pandemic. Healthcare providers should continue to provide education on healthy eating habits and regular exercise. We encourage access to telehealth interventions as adjuncts to paediatric weight management.

The risk of premature atherosclerotic cardiovascular disease (ASCVD) in youth who have had MIS-C is not yet known; however, patients with a history of Kawasaki Disease with residual aneurysmal dilatation are considered high-risk for ASCVD. In MIS-C, coronary artery aneurisms have been found in 6%-24% of patients and Kawasaki disease features have been documented in up to 40%. 77, 78 Recent data suggest that paediatric patients with MIS-C who have been treated with IVIG or IL-6 antagonists such as tocilizumab recover without sequelae. 79 Given the unknown risk of complications, however, longer-term cardiology follow-up is warranted for children who have recovered from MIS-C.

It remains to be determined whether vitamin D replacement will provide protection against COVID-19 or complications. Randomized trials are in progress that will help determine whether vitamin D supplementation can prevent or decrease the severity of COVID-19. • MIS-C appears to increase risk of hypocalcaemia in children, and those who are found to have developed coronary artery aneurisms may be at risk of later ASCVD.

• Children with T1D and higher A1C are more likely to be hospitalized with COVID-19 than children with better diabetes control.

The COVID-19 pandemic has created a number of challenges in paediatric diabetes management related to school closures, disrupted schedules and stress related to diabetes management during periods of lockdown.

• Obesity does not appear to increase risk of acquiring SARS-CoV-2 infection in children, but obesity may be a risk factor for complications of COVID-19 in this population.

• COVID-19 in children with diabetes insipidus requires extra attention to fluid and sodium balance and may require a change in form of desmopressin delivery in those who are using the intranasal form.

We would also like to highlight the importance of recognizing indirect effects of the COVID-19 pandemic on physical activity and eating habits that will worsen the problems of obesity, metabolic syndrome and associated complications due to shelter-in-home mandates and physical distancing restrictions. An acute increase in sedentary behaviour is known to cause decreased insulin sensitivity and elevations in blood glucose and over time increases the risk of incident T2D. [85] [86] [87] We must continue to provide the support our patients require to minimize the health consequences of this pandemic on the next generation.

There were no outside funding sources for this manuscript. 

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

https://orcid.org/0000-0002-2656-7211

Ambika P. Ashraf https://orcid.org/0000-0003-0692-6624

Evgenia Gourgari https://orcid.org/0000-0002-5788-7955

Pathogenesis of COVID-19 from a cell biology perspective

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

COVID-19: a new virus, but a familiar receptor and cytokine release syndrome

COVID-19 in children, pregnancy and neonates: a review of epidemiologic and clinical features

Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2

COVID-19 infection in children and adolescents

Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19

COVID-19 presenting with diarrhoea and hyponatraemia

Acute symptomatic hyponatremia in setting of SIADH as an isolated presentation of COVID-19

Nervous system involvement after infection with COVID-19 and other coronaviruses

Hypocortisolism in survivors of severe acute respiratory syndrome (SARS)

COVID-19-associated ophthalmoparesis and hypothalamic involvement

Association between high serum total cortisol concentrations and mortality from COVID-19

Acute adrenal infarction as an incidental CT finding and a potential prognosis factor in severe SARS-CoV-2 infection: a retrospective cohort analysis on 219 patients

Case report: adrenal pathology findings in severe COVID-19: an autopsy study

SARS-CoV-2: a potential trigger for subacute thyroiditis? Insights from a case report

Thyrotoxicosis in patients with COVID-19: the THYRCOV study

SARS-CoV-2-related atypical thyroiditis

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus

Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report

New-onset diabetes in Covid-19

Hypolipidemia is associated with the severity of COVID-19

Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study

Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19)

Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series

Multisystem inflammatory syndrome in children, the real disease of COVID-19 in pediatrics -a multicenter case series from Al-Ahsa, Saudi Arabia

Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval

Endocrinology in the time of COVID-19: management of diabetes insipidus and hyponatraemia

Abnormal plasma sodium concentrations in patients treated with desmopressin for cranial diabetes insipidus: results of a long-term retrospective study

Clinical insights into adipsic diabetes insipidus: a large case series

Adipsic diabetes insipidus in adult patients

Association between hypernatraemia acquired in the ICU and mortality: a cohort study

American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Endocrinology in the time of covid-19: management of hyperthyroidism and hypothyroidism

Thyroid disease in the time of COVID-19

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical characteristics of coronavirus disease 2019 in China

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

COVID-19 and the cardiovascular system

Type 1 diabetes and COVID-19: preliminary findings from a multicenter surveillance study in the U

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study

Diabetic ketoacidosis at type 1 diabetes diagnosis in children during the COVID-19 pandemic

COVID-19 and children with diabetes-updates, unknowns, and next steps: first, do no extrapolation

Coronavirus lockdown effect on type 1 diabetes management omicronn children wearing insulin pump equipped with continuous glucose monitoring system

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

Severe COVID-19 in children and young adults in the Washington, DC Metropolitan Region

Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian Pediatric Intensive Care Units

COVID-19) in a children's hospital in

SARS-CoV-2 clinical syndromes and predictors of disease severity in hospitalized children and youth

Association of obesity with disease severity among patients with coronavirus disease

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Providing high-quality care remotely to patients with rare bone diseases during COVID-19 pandemic

Vitamin D concentrations and COVID-19 infection in UK Biobank

Vitamin D status in hospitalized patients with SARS-CoV-2 infection

The changing pattern of hypernatremia in hospitalized children

Hypernatremia in critically ill patients

AACE Position Statement: Coronavirus (COVID-19) and people with adrenal insufficiency and Cushing's Syndrome

Endocrinology in the time of COVID-19: management of adrenal insufficiency

Dexamethasone in hospitalized patients with Covid-19 -Preliminary Report

Corticosteroids for COVID-19

COVID-19 epidemic: disease characteristics in children

Epidemiology of COVID-19 among children in China

Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry

Association of Race and Ethnicity with glycemic control and hemoglobin A1c levels in youth with type 1 diabetes

Commentary: COVID-19 in patients with diabetes

People of any age with underlying medical conditions

Clinical considerations for patients with diabetes in times of COVID-19 epidemic

Planning for food access during emergencies: missed meals in Philadelphia

Americans drop kale and quinoa to lock down with chips and oreos

Multisystem inflammatory syndrome in U.S. children and adolescents

Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach

Mapping systemic inflammation and antibody responses in Multisystem Inflammatory Syndrome in Children (MIS-C)

Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study

Fracture prevention with zoledronate in older women with osteopenia

Fracture during intravenous bisphosphonate treatment in a child with osteogenesis imperfecta: an argument for a more frequent, low-dose treatment regimen

Surgical Affairs Committee. Comment on Thyroid Surgery During the Covid-19 Pandemic. 7/13/2020

Physical inactivity rapidly induces insulin resistance and microvascular dysfunction in healthy volunteers

Sedentary behaviors and health outcomes among adults: a systematic review of prospective studies

Determinants of new-onset diabetes in older adults-Results of a national cohort study

SARS-CoV-2 infection and paediatric endocrine disorders: Risks and management considerations